We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Bio-Rad to Integrate CSIRO's MolSAR™ Technology into its KnowItAll Informatics System

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bio-Rad to Integrate CSIRO's MolSAR™ Technology into its KnowItAll Informatics System"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Bio-Rad Laboratories, Inc. has announced plans to integrate MolSAR™ (Molecular Structure Activity Relationships) molecular modeling technology into their KnowItAll® Informatics System as part of a proposed collaborative agreement with the Division of Molecular and Health Technologies of Australia's Commonwealth Scientific and Industrial Research Organisation (CSIRO).

MolSAR™ technology uses Bayesian neural network technology to build in silico models for a wide range of end points such as ADME/Tox properties or biological activities, allowing users to build their own predictive models using in-house experimental data and reference datasets pertaining to ligand moieties.

"Since medicinal chemists often work on compounds pertaining to very specific chemical classes, 'localized' models that are built using in-house data can be an optimal solution," said Bio-Rad's Informatics Division Manager Marketing and Product Manager Omoshile Clement, Ph.D.

Building models to predict the ADME/Tox profile of a drug compound is an area of increasing interest for drug discovery researchers due to the enormous potential of reducing discovery costs and time to market.

Building models "in house" is of interest to pharmaceutical and biotech companies since it provides the ability to create custom models without the risk of disclosing proprietary information to a third party.

"The integration of CSIRO's MolSAR™ technology into our KnowItAll® platform will offer a wider array of in silico solutions," said Bio-Rad's Informatics Division General Manager Gregory M. Banik, Ph.D.

"This partnership will mark a step forward in Bio-Rad's commitment to helping pharmaceutical researchers more effectively employ in silico technologies earlier on in the drug discovery process."

The KnowItAll® platform includes over 30 different pre-built models that can be used to predict properties such as water solubility, plasma protein binding, bioavailability, metabolism, mutagenicity and more.

Using in-house or proprietary datasets, the MolSAR™ algorithm integrated within the KnowItAll® platform will be able to be used to build, refine and/or optimize local models. The KnowItAll® platform can also combine local and global models into a single framework, allowing expanded model usage across broader chemistries.

"We are pleased to have an opportunity to share the benefits of this robust technology with drug discovery researchers around the world," said Dr. David Winkler, lead developer of the MolSAR™ technology at CSIRO.